Solyx Protocol  (U9915)  
Cover Page  
[STUDY_ID_REMOVED] 
A prospective, Non -randomized, Parallel Cohort, Multi- Center Study of the Solyx ‚Ñ¢ Single Incision Sling 
System  Vs. The Obtryx II ‚Ñ¢ Sling System for the Treatment of Women with Stress Urinary Incontinence  
Date Last Updated: August 22, 2018  
[LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 1 of 58 
  
Postmarket Study PS120093  
Solyx‚Ñ¢ Study  
 
CLINICAL PROTOCOL  
 
 
A Prospective, Non-Randomized, Parallel Cohort, Multi-center Study of the Solyx‚Ñ¢ Single 
Incision Sling System vs. the Obtryx‚Ñ¢ II Sling System for the Treatment of Women with 
Stress Urinary Incontinence 
 
Sponsored By  
[CONTACT_712395]. It should be held 
confidential and maintained in a secure location. 
Do not copy or distribute without written permission from [LOCATION_011] Scientific Corporation. 
 
 
 
           
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 1 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 6 of 58 
 
 Postmarket Solyx‚Ñ¢ Study PS120093:  A Prospective, Non -Randomized, 
Parallel Cohort, Multi -center Study of the Solyx ‚Ñ¢ Single Incision Sling 
System vs. the Obtryx‚Ñ¢ II  Sling System for the Treatment of Women with 
Stress Urinary Incontinence  
‚Ä¢ Week 2 Visit  
‚Ä¢ Week 6 Visit  
‚Ä¢ Month 6 Visit 
‚Ä¢ Month 12 Visit 
‚Ä¢ Month 18 Visit 
‚Ä¢ Month 24 Visit 
‚Ä¢ Month 36 Visit (End of study) 
Study 
Duration Approximately [ADDRESS_969082]  enrolled  
Key Inclusion 
Criteria  1. Female ‚â• 18 years of age  
2. Willing and able to comply with the study procedures and provide 
written informed consent to participate in the study (subject or legal representative)  
3. Diagnosed with predominant SUI confirmed by [CONTACT_712396]  (see manual of 
operations) 
4. Confirmed SUI is greater than urge incontinence with MESA 
5. Cystometric capacity ‚â• [ADDRESS_969083]-void residua l (PVR) of < [ADDRESS_969084] Market Study Protocol
Page 6 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 7 of 58 
 
 Postmarket Solyx‚Ñ¢ Study PS120093:  A Prospective, Non -Randomized, 
Parallel Cohort, Multi -center Study of the Solyx ‚Ñ¢ Single Incision Sling 
System vs. the Obtryx‚Ñ¢ II  Sling System for the Treatment of Women with 
Stress Urinary Incontinence  
Key 
Exclusion 
Criteria  1. Subject s who are pregnant, lactating, or planning future pregnancies  
2. Subject s with a chief complaint of overactive bladder  
3. Subjects with a pattern of recurrent urinary tract infections, defined as ‚â• [ADDRESS_969085] infections during a 6-month period prior to surgery or ‚â• [ADDRESS_969086] s with any of the following confounding conditions: 
a. Neurogenic bladder 
b. Urethral stricture and bladder neck contracture 
c. Bladder stones or tumors 
d. Urinary tract fistula or diverticula 
e. Pathology which would compromise implant placement including subjects  currently taking anticoagulation therapy 
f. Pathology that would limit blood supply or infections that would compromise healing  including chemotherapy, systemic steroids 
and systemic immunosuppressants 
9. Subjects with diabetes and an A1c ‚â• 7% 
10. Non-English speaking subject s 
11. Subject s who have participated in an investigational study (medical 
device or drug) within [ADDRESS_969087] Market Study Protocol
Page 7 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 8 of 58 
 
 Postmarket Solyx‚Ñ¢ Study PS120093:  A Prospective, Non -Randomized, 
Parallel Cohort, Multi -center Study of the Solyx ‚Ñ¢ Single Incision Sling 
System vs. the Obtryx‚Ñ¢ II  Sling System for the Treatment of Women with 
Stress Urinary Incontinence  
Primary 
Statistical 
Hypothesis  The single incision sling will be non -inferior to the standard outside -in 
transobturator sling for the treatment of female stress urinar y incontinence  in 
safety and effectiveness at 36 months as compared to Baseline.  
Statistical testing will be performed to determine if success rate of 
improvement in stress urinary incontinence at 36 months of single incision 
sling (treatment) group will be  non- inferior to transobturator device  (control) 
group. The null hypothesis is that the success rate in treatment  group is less 
than or equal to the success rate  in control group minus margin: 
 
ùêªùêªùêªùêª: ùúãùúãùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë° ‚àíùúãùúãùëêùëêùëêùëêùë°ùë°ùë°ùë°ùë°ùë°ùëêùëêùëüùëü ‚â§ ‚àí ‚àÜ    
 
The alternative hypothesis is:  
 
ùêªùêªùêªùêª: ùúãùúãùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë° ‚àí ùúãùúãùëêùëêùëêùëêùë°ùë°ùë°ùë°ùë°ùë°ùëêùëêùëüùëü> ‚àí ‚àÜ     
 
where ùúãùúã ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°ùë°  
 and ùúãùúãùëêùëêùëêùëêùë°ùë°ùë°ùë°ùë°ùë°ùëêùëêùëüùëü are the success rate of improvement in stress 
urinary incontinence at 36 months in treatment group and control group 
respectively, and ‚àÜ  is defined as the non -inferiority margin.  
 
 
 
     
 
 
 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 8 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page [ADDRESS_969088] Market Study Protocol
Page 10 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 12 of 58 
 
 12.3.5.  Changes to Planned Analyses .................................................................... 40  
13. DATA MANAGEMENT  ........................................................................................................ 40  
13.1.  Data Collection, Processing, and Review ............................................................. 40  
13.2.  Data Retention  ........................................................................................................ 40  
14. AMENDMENTS  ................................................................................................................... 41  
15. DEVIATIONS  ...................................................................................................................... 41  
16. DEVICE /EQUIPMENT ACCOUNTABILITY  .......................................................................... [ADDRESS_969089]/ Ethics Committee  ................................................... 44  
17.4.  Sponsor Responsibilities  ........................................................................................ 44  
17.5.  Insurance ................................................................................................................. 44  
18. MONITORING  ..................................................................................................................... 44  
19. POTENTIAL RISKS AND BENEFITS  .................................................................................... 45  
19.1.  General  .................................................................................................................... 45  
19.2.  Anticipated Adverse Events  .................................................................................. 45  
19.2.1.  Mesh Exposure and Erosion Event Classification ..................................... 46  
19.3.  Risks associated with Participation in the Clinical Study  .................................. 47  
19.4.  Risk Minimization Actions  .................................................................................... 47  
19.5.  Anticipated Benefits  ............................................................................................... 47  
 
20. INFORMED CONSENT  ......................................................................................................... 47  
21. SAFETY REPORTING  .......................................................................................................... 49  
21.1.  Definitions and Classification  ............................................................................... 49  
21.2.  Relationship to Study Device(s)  ............................................................................ [ADDRESS_969090] Market Study Protocol
Page 12 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 13 of 58 
 
 21.4.  Investigator Reporting Requirements .................................................................. 51  
 
21.6.  Reporting to Regulatory Authorities / IRBs / ECs / Investigators  .................... 52  
 
 
23. SUSPENSION OR TERMINATION  ......................................................................................... 53  
23.1  Premature Termination of the Study  ................................................................... 53  
23.1.1  Criteria for Premature Termination of the Study  ....................................... 53  
23.2  Termination of Study Participation by [CONTACT_71636]/ EC Approval  .................................................................................................. [ADDRESS_969091] Follow -up ................................. 53  
23.4  Criteria for Suspending/Terminating a Study Center  ........................................ [ADDRESS_969092] Market Study Protocol
Page 13 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969093]‚Äôs participation in th e study is 36 months from study procedure.  
Subjects who undergo a medical intervention (surgical or non- surgical) to treat recurrence, 
persistence of SUI, or a mesh complication will be followed to [ADDRESS_969094] Market Study Protocol
Page 18 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
   
  Page 21 of 58 
 
 who will undergo the surgical placement of a sling as treatment, who may or may not also 
undergo a concomitant procedure (such as pelvic floor prolapse repair).  
To assess for eligibility for this study, inclusion and exclusion criteria are included in Sections 9.[ADDRESS_969095] s who meet all of the following criteria  may be given consideration for inclusion in 
this clinical investigation, provided no exclusion criterion (see Section 9.3 ) is met.  
1. Female ‚â• 18 years of age  
2. Willing and able to comply with the study procedures and provide written informed 
consent to participate in the study (subject or legal representative)  
3. Diagnosed with predominant SUI confirmed by [CONTACT_712396]  (see manual of operations)  
4. Confirmed SUI is greater than urge incontinence with MESA 
5. Cystometric capacity ‚â• [ADDRESS_969096]-void residua l (PVR) of ‚â§ [ADDRESS_969097] infections, defined as ‚â• [ADDRESS_969098] infections during a 6-month period prior to surgery or ‚â• [ADDRESS_969099] s with previous surgical  procedures for SUI including bulking, urethral sling, 
bone anchor, Burch procedure, pubo-vaginal sling, and MMK procedure. Excluding Kelly plication, Botox, anterior repair, or Inter- Stim 
5. Subjects with prior pelvic organ prol apse surgery who experienced mesh 
complications  
6. Subjects with previous radiation therapy to the pelvis 
7. Subjects with known or suspected hypersensitivity to polypropylene mesh 
8. Subjects with any of the following confounding conditions: 
a. Neurogenic bladder  
b. Urethral stricture and bladder neck contracture 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 21 of 58 

PS120093 Confidential        [LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969100] fistula or diverticula  
e. Pathology which would compromise implant placement including subjects  
currently taking anticoagulation therapy 
f. Pathology that would limit blood supply or infections that would compromise healing including chemotherapy, systemic steroids and systemic 
immunosuppressants 
9. Subjects with diabetes and an A1c ‚â• 7%  
10. Non-English speaking subject s 
11. Subjects who have participated in an investigational study (medical device or drug) within [ADDRESS_969101] signed Informed Consent . Subjects will be 
considered Intent- to-Treat (ITT) once the sling  procedure has been initiated  (i.e. anesthe sia 
administered).  All enrolled subject s will be assigned to receive either the treatment or 
control device by [CONTACT_712397] -specific 
centers.  All ITT subjects who receive the assigned device and have no major protocol 
deviations will be considered part of the Per Protocol analysis.      
10.2. Withdrawal 
All subjects enrolled in the clinical study (including those withdrawn from the clinical study 
or lost to follow-up) will be accounted for and documented. If a subject withdraws from the 
clinical investigation, the reason(s) will be recorded .  
Reasons for study withdrawal may include, withdrawn consent, lost to follow-up, subject  
death or other reasons to be documented on the Case Report Form.  
Once a subject  withdraws from the study, the Case Report Form will be completed as 
appropriate up to the point of withdrawal and all Adverse Events shall be closed or 
documented as appropriate.  Withdrawn subject s will be included in the ITT analysis and will 
not be replaced.  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 22 of 58 

PS120093       Confidential  
 
[LOCATION_011] Scientific  
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
Page [ADDRESS_969102] Market Study Protocol
Page 26 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969103] s completing the Month 36 visit will be considered complete.   
11.6. Re-Intervention  
It is the intention of this  study to demonstrate an improvement in stress urinary incontinence 
through clinical effectiveness of a single incision sling.  However, it is recognized that during 
the course of the study, there is a possibility  subjects may require a re-intervention for events 
including but not limited to failed sling repair, persistence of SUI symptoms, or a mesh -
related complication .  A re -intervention may include surgical or non- surgical treatments 
(medical) . For the purpose of this study surgical interventions shall b e classified as ‚Äúre-
surgery‚Äù and non- surgical interventions shall be classified as ‚Äúre-interventions‚Äù.   
Non- surgical interventions  (re-interventions) are defined as office-based procedures and do 
not involve an operating room procedure.  Examples of non-s urgical interventions may 
include but are not limited to an office visit to trim exposed mesh in the vagina or physical 
therapy to treat procedural complications or persistent SUI symptoms .  Data on non- surgical 
interventions will be captured in the CRFs.  Subjects will continue to be followed per the 
regular study visit schedule.   
Surgical interventions ( re-surgery) are surgical operations or procedures performed to correct 
recurring SUI symptoms or a mesh -related complication.  These surgical events typi [INVESTIGATOR_712393] a hospi[INVESTIGATOR_307].  Surgical events 
may include a re- operation to remove mesh material or to loosen the sling  as well as a 
bulking agent application to treat recurrence. The decision to perform a re -surgery will be per 
physician and subject discretion and all re- surgery data will be captured in the Case Report 
Forms.  Subjects undergoing re- surgery to treat recurrence or persistence of SUI symptoms 
are considered treatment failures.  
Subjects under going a re -surgery will be followed to [ADDRESS_969104]  death, results are to be documented in the source documentation and 
Case Report Form  and reported to the Sponsor within the timeframe noted in Table 21.4-1: 
Investigator Reporting Requirements .  If an autopsy is conducted, a copy of the final autopsy 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 31 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969105]‚Äô s medical records, laboratory reports,  clinic charts that correspond to  data recorded 
on the Case Report Forms. In order to comply with these requirements, the following information should be maintained as source documentation, including but not limited to: 
‚Ä¢ Medical history/physical condition of the subject  before enrollment 
‚Ä¢ Protocol entry criteria  
‚Ä¢ Dated and signed notes for specific results of procedures and exams  
‚Ä¢ Laboratory reports 
‚Ä¢ Information related to a dverse events  
‚Ä¢ Re-interventions (including physical therapy, bulking, mesh trimming) 
‚Ä¢ Surgical notes, including subject condition and re -surgery if applicable  
‚Ä¢ Quality of life assessments and VAS pain scales  
‚Ä¢ Discharge Summaries/Procedure reports  
‚Ä¢ Autopsy reports  
Subject data will be recorded  on Case Report Forms which will be prov ided by [CONTACT_712398]. The data reported on the Case Report Forms shall be derived from source documentation and shall be consistent with these source documents.  Any discrepancies shall be explained and documented . Any change or correction made to the 
clinical data will be dated, initialed, and explained, if necessary, and shall not obscure the original entry. An  audit trail shall be maintained which will be made available for review by 
[CONTACT_13668].  Any queries to the data will be addressed by [CONTACT_712399] a timely manner.  
13.2. Data Retention 
The i nvestigator will maintain, at the  investigative site, in original format all essential study 
documents and source documentation that support the data collected on study subjects in compliance with ICH/GCP guidelines.  Documents must be retained for at least [ADDRESS_969106] Market Study Protocol
Page 40 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969107]. These documents will be 
retained for a longer period of time by [CONTACT_712400]. It is BSC‚Äôs responsibility to inform the investigator when these documents no longer need to be maintained. The i nvestigator will take measures to ensure 
that these essential documents are not accidentally damaged or destroyed. If for any reason the investigator withdraws responsibility for maintaining these essential documents, custody must be transferred to an individual who will assume responsibility and BSC must receive written notification of this custodial change.  
14. Amendmen ts  
If a protocol revision is necessary for reasons including but not limited to, the rights, safety 
or welfare of the subject, or scientific integrity of the data, an amendment is required. Appropriate approvals (e.g., IRB/EC/ FDA/CA)  of the revised protoc ol must be obtained 
prior to implementation.  
15. Deviations  
An Investigator must not make any changes or deviate from this protocol, except to protect the life and physical well-being of a subject in an emergency. An investigator shall notify the sponsor and t he reviewing IRB/E C of any deviation from the investigational plan to protect 
the life or physical well -being of a subject in an emergency , and those deviations which 
affect the scientific integrity of the clinical investigation . Such notice shall be given as soon 
as possible, but no later than [ADDRESS_969108] be documented and reported to the Sponsor.  Study centers may also be required to report deviations to their IRB/EC, per local guidelines and government regulations.  
Deviations will be reviewed and evaluated on an ongoing basis and, as necessa ry, appropriate 
corrective and preventive actions (including notification, center re -training, or 
discontinuation) will be put into place by [CONTACT_1034]. 
16. Device/Equipment Accountability  
This is a post-market study and therefore no investigational devices are being used.  All 
commercial and institutional policies regarding but not limited to device use, purchase and/or storage will be followed.   
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 41 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page 42 of 58 
 
 17. Compliance 
17.1. Statement of Compliance  
This stu dy will be conducted in accordance with ICH/GCP Guidelines , ethical principles that 
have their origins in the Declaration of Helsinki, and pertinent individual country laws and 
regulations. The study shall not begin until the required approval/favorable opi[INVESTIGATOR_5698]/EC and/or regulatory  authority has been obtained, as appropriate. Any additional 
requirements imposed by [CONTACT_1201]/EC or regulatory authority shall be followed, if appropriate. 
17.2. Investigator Responsibilities  
The Principal Investigator [INVESTIGATOR_712394], the investigational 
plan/protocol, ISO [ZIP_CODE], ethical principles that have their origins in the Declaration of Helsinki, any conditions of approval imposed by [CONTACT_3488]/EC, and prevailing local and/or country laws and/or regulations, whichever affords the greater protection to the subject. 
The Principal Investigator‚Äôs responsibilities include, but are not limited to, the f ollowing.  
‚Ä¢ Prior to beginning the study, sign the Investigator Agreement and Protocol Signature 
[CONTACT_71660]/her agreement to conduct the study in accordance with the 
protocol. 
‚Ä¢ Provide his/her qualifications and experience to assume responsibility for the proper conduct of the study and that of key members of the center team through up- to-date 
curriculum vitae or other relevant documentation and disclose potential conflicts of interest, including financial, that may interfere with the conduct of the clinical study or 
interpretation of results.  
‚Ä¢ Make no changes in or deviate from this protocol, except to protect the life and physical 
well-being of a subject  in an emergency; document and explain any deviation from the 
approved protocol that occurred during the course of the clinical investigation. 
‚Ä¢ Create and maintain source documents throughout the clinical study and ensure their 
availability with direct access during monitoring visits or audits; ensure that all clinical-
investigation- related records are retained per requirements.  
‚Ä¢ Ensure the accuracy, completeness, legibility, and timeliness of the data reported to the 
sponsor in the CRFs and in all required reports. 
‚Ä¢ Record, report, and assess (seriousness and relationship to the device/procedure) ever y 
adverse event and observed device deficiency.  
‚Ä¢ Report to BSC, per the protocol requirements, all SAEs and device deficiencies that could have led to a SADE. 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 42 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page 43 of 58 
 
 ‚Ä¢ Report to the IRB/EC and regulatory authorities any SAEs and device deficiencies that 
could have l ed to a SADE, if required by [CONTACT_272611]/EC, and supply BSC with any additional requested information related to the 
safety reporting of a particular event.  
‚Ä¢ Allow the sponsor to perform monitoring and auditing ac tivities, and be accessible to the 
monitor and respond to questions during monitoring visits. 
‚Ä¢ Allow and support regulatory authorities and the IRB/EC when performing auditing activities.  
‚Ä¢ Ensure that informed consent is obtained in accordance with this prot ocol and local 
IRB/EC requirements.  
‚Ä¢ Provide adequate medical care to a subject during and after a subject ‚Äôs participation in a 
clinical study in the case of adverse events, as described in the Informed Consent Form (ICF).  
‚Ä¢ Inform the subject of the nature a nd possible cause of any adverse events experienced.  
‚Ä¢ Inform the subject of any new significant findings occurring during the clinical 
investigation, including the need for additional medical care that may be required. 
‚Ä¢ Ensure that clinical medical records are clearly marked to indicate that the subject is enrolled in this clinical study. 
‚Ä¢ Ensure that, if appropriate, subject s enrolled in the clinical investigation are provided 
with some means of showing their participation in the clinical investigation, together with 
identification and compliance information for concomitant treatment measures (contact [CONTACT_5735]). 
‚Ä¢ Inform, with the subject ‚Äôs approval or when required by [CONTACT_2091], the 
subject ‚Äôs personal physician about the subject ‚Äôs participation in the clinical investigation.  
‚Ä¢ Make all reasonable efforts to ascertain the reason(s) for a subject‚Äôs premature 
withdrawal from clinical investigation while fully respecting the subject ‚Äôs rights.  
‚Ä¢ Ensure that an adequate investigation site team and facilities exist and are maintained and 
documented during the clinical investigation. 
‚Ä¢ Ensure that maintenance and calibration of the equipment relevant for the assessment of 
the clinical investigation is appropriately performed an d documented, where applicable. 
17.2.1. Delegation of Responsibility  
When specific tasks are delegated by [CONTACT_2413], included but not limited to conducting 
the informed consent process , the investigator is responsible for providing appropriate 
training and adequate supervision of those to whom tasks are delegated. The investigator is accountable for regulatory violations resulting from failure to adequately supervise the conduct of the clinical study.  
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 43 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969109]/ Ethics Committee  
Prior to gaining Approval- to-Enroll status, the investigational center will provide to the 
sponsor documentation verifying that their IRB/EC is registered or that registration has been 
submitted to the appropriate agency, as applicable according to national/regulatory requirements.   
A copy of the written IRB/ EC and/or competent authority approval of the protocol (or 
permission to conduct the study) and Informed Consent Form, must be received by [CONTACT_712401] s into the. Prior approval must also be obtained for 
other materials related to subject recruitment or which will be provided to the subject. 
Annual IRB/ EC approval and renewals will be obtained throughout the duration of the study 
as required by [CONTACT_5737]/country or IRB/EC requirements. Copi[INVESTIGATOR_5699]‚Äôs reports and the IRB/EC continuance of approval must be provided to the sponsor.  
17.4. Sponsor Responsibilities 
All information and data sent to BSC concerning subjects or their participation in this study 
will be considered confidential by [CONTACT_71640]. Only authorized BSC  personnel or a BSC 
representative will have access to these confidential record s. Authorized regulatory personnel 
have the right to inspect and copy all records pertinent to this study. Study data collected during this study may be used by [CONTACT_113644], publication, and to support future research and/or other business purposes. All data used in the analysis and reporting of this study will be without identifiable reference to specific subject  name.  
BSC will keep subjects ‚Äô health information confidential in accordance with all applicable 
laws and  regulations.  BSC may use subjects ‚Äô health information to conduct this research, as 
well as for a dditional purposes, such as overseeing and improving the performance of its 
device, new medical research and proposals for developi[INVESTIGATOR_71613], and other business purposes. Information received during the study will not be used to market to subject s; subject  names will not be placed on any mailing lists or sold to 
anyone for marketing purposes.  
17.5. Insurance  
Where required by [CONTACT_5737]/country regulation, proof and type of insurance coverage, by [CONTACT_142219]. 
18. Monitoring  
Monitoring will be performed during the study to assess continued compliance with the protocol and applicable regulations. In addition, the monitor verifies that study records are adequately maintained, that data are reported in a satisfactory manner with respect to timeliness, adequa cy, and accuracy, and that the investigator continues to have sufficient 
staff and facilities to conduct the study safely and effectively. The i nvestigator/institution 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 44 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969110] to a quality assurance audit by [CONTACT_5742], as well as 
inspection by [CONTACT_712402]. It is important tha t the investigator and 
relevant study personnel are available during on-site monitoring visits or audits and that sufficient time is devoted to the process.  
19. Potential Risks and Benefits 
19.1. General   
The risks and benefits of performing a suburethral sling procedure in the following subjects should be carefully considered due to additional risks associated with their conditions: 
‚Ä¢ Women planning future pregnancies 
‚Ä¢ Overweight women (weight parameters to be determined by [CONTACT_099]) 
‚Ä¢ Subjects with blood coagulation disorder 
‚Ä¢ Subjects with a compromised immune system or any other condition that would 
compromise healing 
‚Ä¢ Subject s with renal insufficiency or upper urinary tract obstruction  
19.2. Anticipated Adverse E vents   
The following anticipated adverse events (AE)  have b een reported due to suburethral sling 
placement, but are not limited to: 
‚Ä¢ Abscess  
‚Ä¢ Allergic reaction  
‚Ä¢ Bleeding 
‚Ä¢ Bruising/Hematoma  
‚Ä¢ Dehiscence of vaginal incision  
‚Ä¢ Detrusor Instability  
‚Ä¢ De Novo Dyspareunia 
‚Ä¢ Edema/Erythema 
‚Ä¢ Exposure 
‚Ä¢ Erosion 
‚Ä¢ Extrusion 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 45 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page 48 of 58 
 
 [LOCATION_011] Scientific will provide a study- specific template of the ICF to investigators 
participating in this study. The ICF template may be modified to meet the requirements of the 
investigative center‚Äôs IRB/EC.  Any modification requires approval from BSC prior to use of 
the form.  The ICF must be in a language understandable to the subject and if needed, BSC will assist the center in obtaining a written consent translation. Translated consent forms must also have IRB/EC approval prior to their use.  Privacy  language shall be included in the 
body of the form or as a separate form as applicable.   
The process of obtaining Informed Consent shall: 
‚Ä¢ be conducted by [CONTACT_079] [INVESTIGATOR_5704],  
‚Ä¢ include a description of all aspects of the clinical study that are relevant to the subject‚Äôs 
decision to participate throughout the clinical study, 
‚Ä¢ avoid any coercion of or undue influence of subject s to participate,  
‚Ä¢ not waive or appear to waive subject ‚Äôs legal rights,  
‚Ä¢ use native language that is non- technical and understandable to the subject  or his/her 
legal representative,  
‚Ä¢ provide ample time for the subject to consider participation and ask questions if 
necessary,  
‚Ä¢ ensure important new information is provided to new and existing subjects throughout the 
clinical study . 
The ICF shall always be signed and personally dated by [CONTACT_307980].  If a legal representative signs, the subject shall be asked to provide informed 
consent for continued participation as soon as his/her medical condition allows. The original signed ICF will be retained by [CONTACT_71657] a copy of the signed and dated document and any other written information  must be given to the person signing the form.  
Failure to obtain subject  consent will be reported by [CONTACT_71658] (e.g. , FDA requirement is within 5 working days of learning 
of such an event). Any violations of the informed consent process must be reported as deviations to the sponsor and local regulatory authorities (e.g. IRB/EC), as appropriate.  
If new information becomes available that can significantly affect a subject 's future health 
and medical care, that information shall be provided to the affected subject (s) in written form 
via a revised ICF or , in some situations, enrolled subject s may be requested to sign and date 
an addendum to the ICF. In addition to new significant information during the course of a study, other situations may necessitate revision of the ICF, such as if there are amendments to the protocol, a change in P rincipal Investigator, administrative changes, or following 
annual review by [CONTACT_1201]/EC. The new version of the ICF must be approved by [CONTACT_1201]/EC. [LOCATION_011] Scientific approval is required if changes to the revised ICF are requested by [CONTACT_16018]‚Äôs IRB/EC. The IRB/EC will determine the subject population to be re-consented. 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 48 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page 49 of 58 
 
 A Screening/Enrollment Log will be maintained to document select information about 
candidates who fail to meet the general or ‚Äúother specific‚Äù entry criteria.  
21. Safety Reporting  
21.1. Definitions and Classification  
Adverse event definitions are provided in Table 21.1-1. A dministrative edits were made to 
combine definitions from ISO [ZIP_CODE] and MEDDEV 2.7/3 12/2010.  
Table 21.1-1: Adverse Event Definitions  
Term  Definition  
Adverse Event (AE)  
 
Ref: ISO [ZIP_CODE] -2011 
 
Ref: MEDDEV 2.7/3 12/[ADDRESS_969111] clinical signs (including an abnormal laboratory finding) in 
subjects, users or other persons, whether or not related to the investigational medical device.  
NOTE 1: This includ es events related to the investigational medical device 
or comparator.
 
NOTE 2: This definition includes events related to the procedures involved 
(any procedure in the clinical investigation plan).  
NOTE 3: For users or  other persons, this definition is restricted to events 
related to the investigational medical device.  
Serious Adverse Event (SAE)  
 
Ref: ISO [ZIP_CODE] -2011 
 
Ref: MEDDEV 2.7/3 12/2010 Adverse event that:  
‚Ä¢ Led to death , 
‚Ä¢ Led to  serious deterioration in the health of the subject , that either 
resulted in:  
o a life -threatening illness or injury, or  
o a permanent impairment of a body structure or a body function, or  
o in-subject   or prolonged hospi[INVESTIGATOR_272563], or  
o medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function  
‚Ä¢ Led to fetal distress, fetal death, or a congenital abnormality or birth defect.  
NOTE 1: Planned hospi[INVESTIGATOR_272] a pre -existing condition, or a 
procedure requir ed by [CONTACT_5745], without serious 
deterioration in health, is not considered a serious adverse event.  
Device Deficiency  
 
Ref: ISO [ZIP_CODE] -2011 
 
Ref: MEDDEV 2.7/3 12/[ADDRESS_969112] to its 
identity, quality, durability, reliability, safety or performance.  
NOTE 1 : Device deficiencies include malfunctions, misuse or use errors, 
and inadequate labeling.  
 
Abbreviations: EC=Ethics Committee; IRB=Institutional Review Board  
 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 49 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page 50 of 58 
 
 Underlying diseases are not reported as AEs unless there is an increase in severity or 
frequency during the course of the investigation. Death should not be recorded as an AE, but should only be reflected as an outcome of a specific SAE (see Table 21.1-1 for AE definitions).  
Any device related or study procedure related AE experienced by [CONTACT_272617], whether during or subsequent to the procedure, must be recorded in the CRF.   Only device and procedure- related AE‚Äôs are captured in this study.   
Refer to Section 19 for the known risks associated with the study device(s). 
21.2. Relationship  to Study Device(s)  
The i nvestigator must assess the relationship of the AE to the study device as related or 
unrelated. See criteria in Table 21.2-1:  
Table 21.2-1: Criteria for Assessing Relationship of Study Device to Adverse Event  
Classification  Description  
Unrelated  The adverse event is determined to be due to a concurrent illness or effect of another 
device/drug and is not related to the investigational product.  
Related  ‚Ä¢ The adverse event is determined to be potentially related to the investigational 
product, and an alternative etiology is equally or less likely compared to the 
potential relationship to investigational product , or 
‚Ä¢ There is a strong relationship to investigational product, or recurs on re -challenge, 
and another etiology is unlikely , or 
‚Ä¢ There is no other reasonable medical explanation for the event.  
21.3. Relationship to Study Procedure 
The i nvestigator must assess the relationship of the AE to the study procedure as unrelated, 
possibly related, or probably related . See criteria in Table 21.2-1:  
Table 21.3-2: Criteria for Assessing Relationship to Study Procedure  
Classification  Description  
Unrelated  ‚Ä¢ No evidence that the timing of the adverse event has a relationship to  the  
procedure performed.  
Possibly Related  ‚Ä¢ The adverse event has a timely relationship to procedure  performed.   
However, a potential alternative etiology may be responsible for the adverse  
event.  
Probably Related  ‚Ä¢ The adverse event has a timely relationship to the study procedure performed and 
the causative relationship can be clearly established. No potential alternative 
etiology is apparent.  
 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 50 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page 51 of 58 
 
 21.4. Investigator Reporting Requirements  
The communication requirements for reporting to BSC are as shown in Table 21.4-1. 
Table 21.4-1: Investigator Reporting Requirements  
Event Classification  Communication Method  Communication Timeline  
Adverse device Effects and 
Serious Adverse Device 
Effects . 
Events assessed for reporting 
shall include but are not 
limited to: 
‚Ä¢ Mesh exposure in the 
vagina  
‚Ä¢ Mesh erosion into the 
bladder  Complete AE CRF page with all available new and updated information  ‚Ä¢ Within [ADDRESS_969113] becoming aware of the event or 
as per local/regional regulations.  
‚Ä¢ Reporting required through the 
end of the study 
If request ed by [CONTACT_712403] (unidentified) for the 
reported event  ‚Ä¢ When documentation is 
available  
Adverse Events related to the study procedure  for both 
surgical groups.  
Events assessed for reporting 
shall include but are not 
limited to: 
‚Ä¢ Organ perforation  
‚Ä¢ Bleeding (including hemorrhage and 
hematoma)  
‚Ä¢ Pelvic pain  
‚Ä¢ Infection  
‚Ä¢ De novo dyspareunia  
‚Ä¢ Urinary retention  
‚Ä¢ Recurrent 
incontinence  
‚Ä¢ Other urinary problems  
‚Ä¢ Neuromuscular problems  
‚Ä¢ Revision/re -surgery  
 Complete the AE CRF page, which 
contains such information as onset date 
of the AE, treatment provided if any, resolution, assessment of seriousness, 
and relationship to study device.  ‚Ä¢ Within [ADDRESS_969114] becoming aware of the event or 
as per loc al/regional regulations.  
‚Ä¢  
‚Ä¢ Reporting required through end 
of subject participation  
Device Deficiencies  (including 
but not limited to f ailures, 
malfunctions, and product 
nonconformities ) 
Note:  Any Investigational 
Device Deficiency that might 
have led to a serious adverse 
event if a) suitable action had Complete CRF  with all available new 
and updated information ‚Ä¢ Within [ADDRESS_969115] 
becoming aware of the event and 
as per local/regional regulations  
‚Ä¢ Reporting required through the 
end of the study 
[LOCATION_011] Scientific Confidential. Unauthorized use is prohibited.
Released
Solyx Post Market Study Protocol
Page 51 of 58 

PS120093 Confidential        [LOCATION_011] Scientific 
Protocol U9915 ‚Äì Solyx vs. Obtryx 
 
  Page [ADDRESS_969116] Market Study Protocol
Page 58 of 58 
